Advertisement

PentaVision

Retinal Physician

Article | 2025 Euretina Congress

Head-to-Head Trial Compares Iluvien and Anti-VEGF

Patients with diabetic macular edema who received the Iluvien implant needed less than half as many injections as those treated with aflibercept alone.

Retinal Physician September 4, 2025
5 Key Takeaways

  • 1

    The NEW DAY trial compared Iluvien to aflibercept in patients with early diabetic macular edema.

  • 2

    Patients receiving Iluvien required an average of 3.4 injections over 18 months, significantly fewer than the 7.5 injections for aflibercept.

  • 3

    One-third of patients in the Iluvien group did not need any supplemental injections during the study.

  • 4

    The mean time from the last injection to the first supplemental injection was longer for Iluvien at 185.4 days.

  • 5

    The trial's findings suggest that long-acting corticosteroid implants may be beneficial in the DME treatment pathway.